Clinical Trials Directory

Trials / Completed

CompletedNCT00091182

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
180 (actual)
Sponsor
National Cancer Institute (NCI) · NIH
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.

Detailed description

OBJECTIVES: I. Determine the response rate in children with recurrent or refractory solid tumors treated with oxaliplatin. II. Determine the cumulative toxicity of this drug in these patients. III. Determine the pharmacokinetic profile of this drug in these patients. IV. Determine time to progression and overall survival of patients treated with this drug. V. Correlate the extent of oxaliplatin exposure with response in these patients. OUTLINE: This is a multicenter study. Patients are stratified according to disease type. Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.

Conditions

Interventions

TypeNameDescription
DRUGoxaliplatinGiven IV

Timeline

Start date
2004-10-01
Primary completion
2006-02-01
First posted
2004-09-09
Last updated
2013-06-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00091182. Inclusion in this directory is not an endorsement.